Latest SLE Stories
Copenhagen, Denmark, Friday 12 June 2009: 92.8% of patients with systemic lupus erythematosus (SLE) suffer anxiety and depression which significantly affects both their physical and emotional quality of life
DNA vaccination using lupus autoantigens and interleukin-10 (IL-10, a cytokine that plays an important role in regulating the immune system) has potential as a novel therapy to induce antigen specific tolerance and may help to prevent kidney damage in patients with systemic lupus erythematosus (SLE), according to a new study presented today at EULAR 2009
- Phase 2 continuation data demonstrated sustained improvement in disease activity and patient response rate through four years of BENLYSTA therapy - - Frequency of disease flares as measured by the SELENA SLEDAI flare index and by BILAG A or B organ domain scores decreased over four years of BENLYSTA therapy - - No increase in overall adverse events, serious adverse events, malignancies or serious infections over time - ROCKVILLE, Md., June 11 /PRNewswire-FirstCall/ -- Human Genome...
The sense of smell is a complex process of the central nervous system that involves specific areas of the brain. In fact, olfactory dysfunction is seen in various central nervous system disorders that involve immune-mediated mechanisms, such as Parkinsonâ€™s disease, schizophrenia, Alzheimerâ€™s disease and multiple sclerosis.
Study found use of oral contraceptives was associated with an increased risk of SLE, particularly among women who had recently started taking them.
Mice from a strain that ordinarily develops systemic lupus erythematosus (SLE), but bred with a deficiency in receptor for the protein Interleukin 21, stayed healthy and exhibited none of the symptoms of the disease, researchers at The Jackson Laboratory and National Institutes of Health report.
Active Biotech (NASDAQ OMX Nordic: ACTI) has presented data regarding the 57-57 project at the American College of Rheumatology (ACR) Annual Scientific Meeting, a premier event for specialists in the field of rheumatology, held in San Francisco October 24-29*.
ROCKVILLE, Md., Aug. 27 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc.
NEW YORK (Reuters Health) - A small study has shown that the osteoporosis drug raloxifene, sold as Evista, helps maintain bone mineral density (BMD) in menopausal women with systemic lupus erythematosus (SLE) who are on corticosteroids.
Cerebellar atrophy has been recognized as an occasional feature of systemic lupus erythematosus (SLE)1,2 but not systemic sclerosis.